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The human papillomavirus 16 E7 protein (HPV 16 E7) transactivates the adenovirus E2 promoter (AdE2) by altering
interactions between retinoblastoma (pRb) family members and the transcription factor E2F. To understand factors limiting
the oncogenic potential of HPV 6, the relative ability of HPV 6 E7 as compared to HPV 16 E7 to transactivate the AdE2
promoter was determined. In primary baby rat kidney cells and human foreskin keratinocytes, HPV 16 E7 transactivated
the AdE2 promoter to a greater extent than HPV 6 E7, consistent with the observation that HPV 16 E7 binds pRb with
greater affinity. HPV 6 E7 gain of function correlated with increasing the affinity of the HPV 6 E7 pRb binding site of
conserved region 2 (CR2). In keratinocytes, in contrast to the AdE2 promoter, the abilities of the two E7 proteins to
transactivate the B-myb promoter, a promoter regulated by E2F bound to p107/p130, were comparable. Introducing a
negative charge into the N-terminus (CR1) and a high affinity pRb binding site into CR2 of HPV 6 E7 resulted in a transactivator
with greater activity than HPV 16 E7 for both the AdE2 and B-myb promoters. Both of the promoters were negatively
regulated by E2F and transactivation by the E7 proteins required an intact E2F site. In C33-A cells, which contain a mutated
pRb, the two E7 proteins had comparable transactivating activity on both the AdE2 and B-myb promoters. The data are
consistent with the interpretation that HPV 16 E7 affects interactions of pRb and p107/p130 with the E2F transcription
factor, whereas HPV 6 E7 only affects interactions of p107/p130. q 1997 Academic Press
INTRODUCTION et al., 1988), cooperate with ras to transform primary
rodent cells (Phelps et al., 1988; Storey et al., 1988),
Human papillomaviruses (HPVs) are the causative immortalize primary keratinocytes (Halbert et al., 1991),
agents of benign papillomas/warts and are risk factors and abrogate growth arrest mediated by DNA damage
for the development of carcinomas of the respiratory or differentiation (Demers et al., 1994, 1996). Both pro-
tract, epidermis, and genital tract. There are over 70 HPV teins are 98 amino acids in length. HPV 16 E7 migrates
types, defined by genotype rather than serotype. Within aberrantly in SDS –polyacrylamide gels due to greater
the genital tract, HPV 6 and HPV 11 DNAs are the pre- negative charge in its N-terminus compared to HPV 6
dominant types found in condyloma acuminata (genital E7 (Armstrong and Roman, 1992, 1993). Both E7 proteins
warts), while HPV 16 and HPV 18 DNAs are the predomi- are substrates for casein kinase II (CKII), but the enzyme
nant types associated with cervical carcinoma. Thus, has a higher affinity for HPV 16 E7 (Firzlaff et al., 1989;
HPV 6 and HPV 11 are referred to as low risk (with Barbosa et al., 1990). In vitro, HPV 6 E7 is a substrate
respect to cervical cancer) and HPV 16 and HPV 18 are for protein kinase C (PKC) while HPV 16 E7 is not (Arm-
referred to as high risk. HPV 16/18 can transform perma- strong and Roman, 1995).
nent rodent cell lines, cooperate with an activated ras HPV 16 E7 transactivation of the adenovirus E2 (AdE2)
gene to transform primary rodent cells, and immortalize promoter is indirect and is mediated through the E2F site
their natural host cell, the keratinocyte. HPV 6/11 have in the promoter (Phelps et al., 1991). That is, HPV 16 E7
little, if any, activity in these assays. binds pRb resulting in the release of the E2F transcription
The difference in oncogenic potential of the high and factor which, in turn, binds the E2F responsive element
low risk viruses correlates with functional differences and transactivates the AdE2 promoter. Experiments to as-
between their E7 proteins. HPV 16 E7, but not HPV 6 sess the interaction of E7 protein with pRb family members
E7, can transform permanent rodent cell lines (Vousden have ranged from establishing relative affinities of such
interactions to determining the functional outcome of the
interaction. A variety of in vitro and in vivo studies have
1 Present address: Department of Dermatology, Indiana University revealed that HPV 16 E7, as compared to HPV 6 E7, has
School of Medicine, Indianapolis, IN 46202. a greater affinity for pRb, p107, and p130 (Gage et al.,2 To whom correspondence and reprint requests should be ad-
1990; Ciccolini et al., 1994; Hu et al., 1995; Demers et al.,dressed at Department of Microbiology and Immunology, Indiana Uni-
1996). Functional studies conducted in the pRb-negativeversity School of Medicine, Indianapolis, IN 46202-5120. Fax: (317) 274-
4090. E-mail: aroman@indyunix.iupui.edu. SAOS 2 cell line indicate that overexpression of pRb inhib-
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its E2F-mediated expression; HPV 16 E7 can reverse this nt 085 to /15 of each promoter, to obtain products with
NdeI and XbaI sites at the 5* end and HindIII and PvuIIinhibition but HPV 6 E7 cannot (Ciccolini et al., 1994). Also,
sites at the 3* end. The PCR products were cloned intoGST–16E7 fusion proteins incubated with preformed pRb/
pUC19 which had been cleaved with SmaI. Each pro-E2F complexes and an E2F element disrupt the pRb:E2F
moter region was excised with NdeI and HindIII andcomplex approximately fivefold better than do GST/6E7
cloned into pRSVluc, which had been digested with NdeIfusion proteins (Wu et al., 1993). HPV 16 E7 expression
and HindIII and gel purified to remove the RSV regulatoryresults in a decrease in the half-life of pRb and p107
region. All plasmids were verified by sequencing the pro-proteins (Boyer et al., 1996, Jones and Munger, 1997);
moter insertion. pGL2-(0536) and pGL-(0536)mut (Lamsimilar data have not been reported for HPV 6 E7.
and Watson, 1993), wild type (E2F/), and mutant (E2F0)The greater affinity of HPV 16 E7 for pRb family mem-
B-myb promoters, respectively, were provided by Rogerbers suggests that HPV 16 E7 would transactivate the
Watson (St. Mary’s Hospital Medical School, London, UK).AdE2 promoter better than HPV 6 E7. The limited data in
Effector plasmids. The DNAs from which E7 se-the literature are inconsistent with respect to the relative
quences were subcloned were HPV6aW50 [originallyability of HPV 6 E7 versus HPV 16 E7 to transactivate the
called HPV6-W50 (Farr et al., 1991)] and HPV 16 (DurstAdE2 promoter. In NIH3T3 cells, HPV 6 E7 transactivates
et al., 1983), the latter obtained from Harold zur Hausenmuch less well than HPV 16 E7 (Storey et al., 1990b),
(Deutsches Krebsforschungszentrum, Heidelberg, Ger-whereas in CV-1 and Rat 3Y1 cells the activities of the
many). The HPV 6 E7 mutants were generated using thetwo proteins are roughly comparable (Munger et al., 1991;
Amersham Oligonucleotide-directed in vitro Muta-Watanabe et al., 1992). We report here that the relative
genesis system (Armstrong, 1995). The nomenclatureability of HPV 6 E7 to transactivate an E2F-responsive
used to designate the mutations in the backbone of thepromoter is both promoter- and cell-specific. In primary
HPV 6 E7 protein is, in order, the original amino acid,baby rat kidney (BRK) cells and human foreskin keratino-
the amino acid position, and the substituted amino acid.cytes (HFKs), HPV 16 E7 transactivates the AdE2 promoter
The nucleotide sequences of the primers used to intro-several-fold better than HPV 6 E7. In contrast, in HFKs the
duce mutations were the following with the mismatchedB-myb promoter is transactivated comparably by HPV 6
bases italicized: p6E7R4DV6PK9H 5*-TACAATATCATGTAG-E7 and HPV 16 E7. In C33-A cells, both promoters are
GGTAGGATGATCTCCATGCAT-3*; p6E7G22DH24Y 5*-CTC-transactivated to the same extent by both E7 proteins.
ATAGCAGTATAAATCTACAGGGTC-3*; p6E7V37DE39I 5*-
TCCGTCCACTATGTCATCCTCATCTTC-3*. The oligonu-MATERIALS AND METHODS
cleotides used to introduce the T7A and T7D mutations
Plasmids into 6E7G22DH24Y were 5*-CCTTTAGGGCAACATGTCT-
TCC-3* and 5*-CCTTTAGGTCAACATGTCTTCC-3*, re-Reporter plasmids. To construct pAdE2luc, the AdE2
spectively. Wild-type and mutant E7 sequences were am-promoter was amplified by PCR using pEC113 (Imperiale
plified by PCR and cloned into the SmaI site of pUC19. Allet al., 1985), provided by Mary Loeken (Harvard Medical
plasmids were verified by sequencing the E7-encodingSchool, Boston, MA), as template. Primers were designed
portion. To construct RSV E7 expression plasmids, SV40to amplify the region from nt 0115 to /15, to obtain a
large T antigen coding sequences were removed fromproduct with an NdeI restriction site at the 5* end and
pRSVTag by digestion with HindIII and BclI and replacedHindIII and PvuII restriction sites at the 3* end. After
with HPV 6 E7 sequences [subcloned from the respectivesubcloning the PCR product into pUC19 and sequencing
pUC19/E7 plasmids cleaved with HindIII and BamHIthe AdE2 insertion, pAdE2 was constructed by excising
(Armstrong, 1995)]. To serve as vector control, pRSV,the AdE2 promoter from pUC19 with NdeI and PvuII and
which contains the regulatory region but no E7 se-cloning it into pRSVTag (provided by Bruce Howard, Na-
quences, was generated by repair of the HindIII andtional Institutes of Health, Bethesda, MD), which had
BclI ends and ligation. To construct SVL E7 expressionbeen cleaved with the same enzymes to remove the RSV
plasmids, pSVL (Pharmacia) was digested with BamHIregulatory region and large T antigen coding sequences.
and E7 sequences excised from pUC19/E7 with BamHIPlasmid pRSVluc (de Wet et al., 1987), provided by Yu-
were inserted (Armstrong, 1995).Chung Yang (Indiana University School of Medicine, Indi-
Internal control plasmids. pRSVbgal (Thierry and Yaniv,anapolis, IN), was digested with HindIII and SmaI to iso-
1987) was supplied by Francoise Thierry (Pasteur Insti-late the 1.8-kb luciferase coding region. This fragment
tute, Paris, France). pSLVbgal was constructed by digest-was subcloned into pAdE2, which had been digested
ing pCMVb (Clontech) with BamHI, purifying the 3.5-kbwith HindIII and HpaI, to yield pAdE2luc. The starting
band encoding b-galactosidase and subcloning it intomaterials for the construction of pMLAdE2(E2F/) and
pSVL (Pharmacia), linearized at the BamHI site.
pMLAdE2(E2F0) were pE2w.t.CAT and the parent plas-
Cells and transfection protocolsmid mutated in the two E2F sites (064 to 060 and 045
to 036), provided by Mary Loeken (Loeken and Brady, Primary baby rat kidney (BRK) cell cultures were initi-
ated from 5- to 8-day-old baby Fisher rats, essentially1989). Primers were designed to amplify the region from
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as described by van der Eb and Graham (1980). The cysteine and methionine and containing 5% dialized fetal
calf serum. Cells were lysed in 0.1% NP-40, 0.25 M NaCl,equivalent of 0.5 kidney per 10-cm dish was plated in low
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) 5 mM EDTA, and 50 mM Hepes, pH 7.5, to which 0.5
mM DTT and 0.2 mM PMSF had been added. Cellularsupplemented with 10% fetal calf serum, 4 mM glutamine,
and 1% antimycotic/antibiotic solution (final concentra- debris was removed by centrifugation and soluble pro-
teins were incubated with either HPV 6 E7 polyclonaltion of 100 U penicillin, 100 mg streptomycin, and 250
ng Amphotericin B). At approximately 60% confluence, antiserum (Armstrong and Roman, 1993) or a cocktail of
pRb monoclonal antisera (Triton Diagnostics and UBI).cells were transfected with a total of 20 mg of DNA, which
included 4.7 mg of effector (RSV, RSV6E7, RSV16E7, or The immune complexes were precipitated with protein
G(/) and A agarose (Oncogene Science). Proteins weremutant E7), 8.5 mg RSVbgal, and 7 mg AdE2luc, using
the optimized calcium phosphate method of Chen and separated by electrophoresis through an 8% SDS–poly-
acrylamide gel and protein visualized by autoradiogra-Okayama (1987). Primary human foreskin keratinocytes
(HFK) were initiated as described previously by Pattison phy. A parallel gel was transferred to PVDF and incu-
bated with goat anti-mouse IgG conjugated to alkalineet al. (1997) and transfected using the method of Farr et
al. (1987), as modified by Dollard et al. (1993) in 12-well phosphatase (Boehringer-Mannheim) and reactions
were visualized with Nitro blue tetrazolium and 5-bromo-plates. A total of 2.5 mg of DNA per well, containing
0.5 mg reporter plasmid (AdE2luc, GL2-(0536)), or E2F 4-chloro-3-indolyl phosphate.
mutants thereof), 1.9 mg effector DNA (RSV, RSV6E7,
RSV16E7, or mutant E7), and 0.1 mg CMVbgal, was used.
RESULTS
C33-A cells, a human cervical carcinoma cell line lacking
HPV DNA, were obtained from Lou Laimins (Northwest- Gain of function in transactivation by HPV 6 E7 maps
ern University School of Medicine, Chicago, IL). Cells to the pRb binding domain of CR2
were maintained in high glucose DMEM plus 10% fetal
calf serum. Cells were plated into 12-well plates at 2.8 We examined the ability of HPV 6 E7 and HPV 16 E7
to transactivate the AdE2 promoter in primary baby rat1 105/well and the following day transfected with 0.05
mg reporter plasmid (AdE2luc or GL2-(0536)), 0.95 mg kidney (BRK) cells because in these cells HPV 16 E7 but
not HPV 6 E7 can cooperate with ras to yield morphologi-effector (SVL, SVL6E7, or SVL16E7), and 0.05 ml SVLbgal.
COS-7 cells (Gluzman, 1981) were plated in high glucose cal transformants (Phelps et al., 1988; Storey et al., 1988).
BRK cells were cotransfected with pRSVE7 and pAdE2-DMEM plus 10% fetal calf serum at 1.3 1 106 cells per
10-cm dish the day before the transfection. Cells were luc. While HPV 6 E7 transactivated the AdE2 promoter
approximately 3-fold, HPV 16 E7 transactivated the pro-transfected with 13 mg DNA and 40 ml lipofectAmine
(Gibco-BRL) in a total volume of 1350 ml DMEM. moter approximately 12-fold (Fig. 1A).
Three domains of HPV 16 E7 play a role in transactiva-
b-Galactosidase and luciferase assays tion, the N-terminal domain, the pRb binding domain, and
the casein kinase II (CKII) binding domain (Edmonds and
Plates or wells were harvested 48 h after transfection
Vousden, 1989; Banks et al., 1990; Storey et al., 1990a;
for b-galactosidase and luciferase assays. To prepare
Phelps et al., 1992; Watanabe et al., 1992; Brokaw et al.,
BRK cell lysates, cell monolayers were washed twice
1994). To assess the role of region 1 (CR1), region 2 (the
with phosphate-buffered saline, lysis solution (100 mM
pRb binding domain of CR2), and region 3 (the CKII site
potassium phosphate, pH 7.8, 0.2% Triton X-100, and 1
of CR2) in transactivation, we monitored the activities of
mM DTT) was added, cells were detached by scraping,
HPV 6 E7 mutants containing amino acid substitu-
and cell debris was removed by centrifugation. For HFKs
tions in one or more of these regions (Fig. 1B). Gain of
and C33-A cells, cells were lysed following the protocol
function for transactivation by HPV 6 E7 correlated with
from the Galacto-Light assay kit (TROPIX, Inc.). For all
changing region 2 (Fig. 1A). To verify that HPV 6 E7R2
cell lysates, chemiluminescent detection of the b-galac-
(HPV 6 E7G22DH24Y) had an increased affinity for pRb, the
tosidase was quantified using the same kit, in a Berthold
ability of wild-type and mutant HPV 6 E7 proteins to inter-
Lumat luminometer following the protocol supplied by
act with pRb was determined. COS-7 cells were trans-
the manufacturer. The chemiluminescent assay for lucif-
fected with plasmids encoding wild-type and mutant HPV
erase was quantified in the luminometer.
E7 proteins under the regulation of the SV40 late pro-
moter, SVL. In this cell line endogenous SV40 T antigenCoimmunoprecipitation
amplifies the E7 expression plasmid as well as aug-
menting E7 transcription. Coimmunoprecipitation assaysCOS-7 cells were transfected as described above.
Forty-eight hours posttransfection, cells were starved for revealed that HPV 6 E7R2 was a better binder of pRb than
wild-type HPV 6 E7 (Fig. 2). In vivo labeling also indicatedcysteine and methionine for 1 h and then labeled for 1
h with 500 mCi Trans35S-Label, sp. act. 1000 Ci/mmol, that all HPV 6 E7 mutants were stable phosphoproteins
(data not shown).37 TBq/mmol (ICN Biochemicals) in DMEM lacking
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affinity for pRb, Figs. 1B and 2) increased the ability of
HPV 6 E7 to transactivate the AdE2 promoter. In marked
contrast to the results obtained in BRK cells, altering
region 1 and 2 consistently resulted in a supertransacti-
vator, i.e., HPV 6 E7R1/2 was, on average, 40% more active
than HPV 16 E7. Altering the CKII site (HPV 6 E7R3) de-
creased HPV 6 E7-mediated transactivation and when
the region 3 mutations were added to the region 1 / 2
mutant (HPV 6 E7R1/2/3), the activity of the supertransacti-
vator was reduced to that of HPV 16 E7.
The relative ability of HPV 6 E7 and HPV 16 E7
proteins to transactivate E2F-responsive elements is
promoter- and cell-dependent
Data from Carlotti and Crawford (1993) suggest that
transactivation of the AdE2 promoter is regulated by both
pRb and p107 or p130. In contrast, the B-myb promoter
is preferentially regulated by E2F bound to p107 and
p130, but not pRb (Lam and Watson, 1993; Lam et al.,
1994, 1995). Therefore we looked at the capacity of HPV
6 E7 versus HPV 16 E7 to activate this promoter in HFKs.
In contrast to what was seen with the AdE2 promoter,
the B-myb promoter was transactivated equally by HPV
FIG. 1. (A) In BRK cells, gain of function in transactivation by HPV 6
E7 of the AdE2 promoter maps to the pRb binding domain of CR2. BRK
cells were cotransfected with pAdE2luc, an internal control, and vector,
HPV 6 E7, HPV 16 E7, or HPV 6 E7 mutants. Results were normalized
first to the internal control and subsequently to the vector control and
represent the average { SD of three experiments each conducted in
duplicate. (B) Alignment of N-terminal sequences of wild-type HPV 6
and HPV 16 E7. Site-directed mutagenesis was used to exchange spe-
cific amino acids as described under Materials and Methods. Periods
within the sequence reflect gaps introduced to achieve maximum
amino acid identity. , identical residues; *, acceptable substitutions.
Region 1 contains amino acids similar to adenovirus E1A conserved
region 1 (CR1); region 2 and region 3 contain amino acids similar to
the pRb binding site and CKII site, respectively, of CR2. In the figures
and text, HPV 6 E7 region 1 (R1), HPV 6 E7R4DV6PK9H; HPV 6 E7 region
2 (R2), HPV 6 E7G22DH24Y; HPV 6 E7 region 3 (R3), 6E7V37DE39I. The nomen-
clature used to designate the mutation is explained under Materials
and Methods.
Gain of transactivation by HPV 6 E7 in human
foreskin keratinocytes maps to CR2 while changes in
CR1 and CR2 result in a supertransactivator
Human keratinocytes are the relevant target cell for
FIG. 2. HPV 6 E7R2 has an increased affinity for pRb. (A) COS-7 cellsthe HPVs under study. Therefore, we next compared the
were transfected with plasmids encoding either wild-type or mutant
transactivational activities of HPV 6 E7 and HPV 16 E7 HPV 6 E7 driven by the SVL promoter or vector alone, pSVL, as indicated
on the AdE2 promoter in human foreskin keratinocytes at the top of the lanes. Proteins were labeled with 35S-Trans label,
immunoprecipitated with antibodies to HPV 6 E7, and separated on 8%(HFKs). As with BRK cells, HPV 16 E7 was more active
SDS–polyacrylamide gels. The extreme right lane was immunoprecipi-than HPV 6 E7; HPV 16 E7 transactivated approximately
tated with antibodies to pRb. Note several extra bands in the pSVL5.5-fold while HPV 6 E7 transactivated 2.5-fold (Fig. 3).
HPV 6 E7 region 2 lane. The running conditions were designed to
The HPV 6 E7 region 1, 2, and 3 mutants were also obtain separation of cellular proteins but not characterization of the E7
analyzed for their ability to transactivate the AdE2 pro- proteins. (B) A parallel gel was transferred to nitrocellulose and incu-
bated with antibodies to pRb.moter. As in BRK cells, HPV 6 E7R2 (i.e., increasing the
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HPV 6 E7T7D/R2 is a supertransactivator of both the
AdE2 promoter and the B-myb promoter
The finding that introducing amino acids from HPV 16
E7 regions 1 and 2 into HPV 6 E7 resulted in a supertrans-
activator raises the possibility that an interaction with
region 1 negatively regulates the transactivation potential
of HPV 6 E7. Since region 1 of HPV 6 E7 encompasses
the protein kinase C (PKC) phosphorylation site (Arm-
strong and Roman, 1995), it is possible that, in addition
to a low affinity pRb binding site, PKC negatively modu-
lates the activity of HPV 6 E7. Alternatively, the increased
activity could be due to the introduction of the greater
FIG. 3. In HFKs, gain of transactivation by HPV 6 E7 of the AdE2
promoter maps to region 2 (the pRb binding domain of CR2), but addi-
tional activity is manifested when region 1 (CR1) and region 2 are
mutated. HFKs were cotransfected with pAdE2luc, an internal control,
and vector, HPV 6 E7, HPV 16 E7, or HPV 6 E7 mutants. Results were
normalized first to the internal control and subsequently to the vector
control and represent the average { SD of two experiments each
conducted in duplicate.
16 E7 and HPV 6 E7 (Fig. 4A). This result suggests that
HPV 6 E7 and HPV 16 E7 can regulate p107 equally.
BRK cells and HFKs are early passage cell populations
that contain wild-type pRb. In contrast, C33-A cells are
an HPV-negative cervical carcinoma cell line which is
mutated in pRb (Scheffner et al., 1991). Thus, one would
not anticipate that HPV 16 E7’s capacity to regulate pRb
would have any consequence in these cells. In C33-A
cells, HPV 6 E7 and HPV 16 E7 had comparable transacti-
vating activity on both the AdE2 and B-myb promoters
(Fig. 4B). These results are consistent with the hypothe-
sis that HPV 16 E7’s greater capacity, over that of HPV
6 E7, to activate the AdE2 promoter in BRK and HFKs, is
related to its greater capacity to bind and inactivate pRb.
The E2F site is necessary for HPV 6 E7-mediated
transactivation
To verify that HPV 16 and HPV 6 E7 transactivation of
the AdE2 and B-myb promoters required an E2F site, we
compared the activities of the E7 proteins on the wild-
type and E2F-site deficient promoters. In HFKs, both of
the wild-type promoters were negatively regulated by the
E2F transcription factor (Figs. 5A and 5B). In the absence
of E7 (vector alone), the value of luciferase was higher
when the promoter was mutated than when it was wild
type. When the luc activity from cells containing vector
FIG. 4. The relative ability of HPV 6 E7 and HPV 16 E7 proteins toand AdE2(E2F0) or vector and B-myb(E2F0) was set to
transactivate E2F-responsive elements is promoter- and cell-depen-1, no transactivation above this value is seen with the
dent. (A) HFKs were transfected as described in the legend to Fig. 3
introduction of either HPV 16 or HPV 6 E7 protein (Figs. with AdE2 or B-myb as the promoter driving luc. (B) C33-A cells were
5A and 5B), indicating that the E2F site is necessary for the recipient of the transfected DNA. Results represent the average {
SD of two experiments each conducted in duplicate.E7-mediated transactivation.
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negative charge of HPV 16 E7 CR1 into HPV 6 E7 CR1
(Armstrong and Roman, 1993). To test these possibilities,
the experimentally determined phosphoacceptor, the
threonine at amino acid residue 7 of HPV 6 E7, was
FIG. 6. The AdE2 and B-myb promoters are supertransactivated by
6E7T7D/R2 (A) HFKs were cotransfected as described in the legend
to Fig. 3 with pAdE2luc. Results represent the average { SD of two
experiments, each conducted in duplicate with at least two different
DNA preparations of each E7-expressing plasmid. (B) HFKs were co-
transfected as described in the legend to Fig. 4 with B-myb as the
promoter driving luc. Results show the average { SD of a representa-
tive experiment conducted in duplicate with at least two different DNA
preparations of each E7-expressing plasmid.
mutated to either alanine or aspartic acid, and the HPVFIG. 5. The AdE2 and B-myb promoters are E2F-dependent and
E7-mediated transactivation is via the E2F element. (A) HFKs were 6 E7 protein tested for transactivation ability with each
cotransfected as described in the legends to Figs. 3 and 4 with the mutation in the context of the high affinity pRb binding
exception that the wild-type (E2F/) and mutated (E2F0) AdE2 promot- site. The supertransactivator phenotype was seen with
ers was derived from pE2w.t.CAT rather than pEC113 (see Materials
HPV 6 E7T7D/R2 but not with HPV 6 E7T7A/R2 (Fig. 6A).and Methods). The wild-type (E2F/) is not transactivated as well as
To assess whether the supertransactivator phenotypepEC113 and, thus, the difference between HPV 6 E7 and HPV 16 E7
is less clear using these constructs. To determine the effect of mutating was due to interactions with p107/E2F- and/or pRb/E2F-
the E2F site on the activity of the promoter, the left two blocks of data mediated promoters, the activity of the HPV 6 E7 mutants
were normalized to cotransfections containing vector plus wild-type was determined on the B-myb promoter. Introduction of
pMLAdE2luc (E2F/). To determine the ability of the E7 proteins to
the high affinity pRb binding site into HPV 6 E7 (HPV 6transactivate the E2F0 promoter, the right group was normalized to
E7R2) had no greater activity on the B-myb promoter thanvector plus pMLAdE2 (E2F0). (B) Similar results are presented using
the B-myb wild-type and E2F– promoters. did wild-type HPV 6 E7 (data not shown). As was seen
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with the AdE2 promoter (Figs. 3 and 6A), HPV 6 E7R1/2 of HPV 6 E7R1/2/3 is equivalent to HPV 16 E7 (Fig. 3).
The data suggest that the CKII site of CR2 may serve towas a supertransactivator of the B-myb promoter (Fig.
6B). Introducing a negative charge into the CR1 of HPV balance the activity of the N-terminus and pRb binding
site of HPV 16 E7. This is unexpected, however, since6 E7 in combination with a high affinity pRb binding site
(HPV 6 E7T7D/R2) also resulted in production of a super- published data indicate that HPV 16 E7 mutants altered
in either the CKII recognition sequence or the phos-transactivator (Fig. 6B).
phoacceptor show no increase in ability to transactivate
the AdE2 promoter (Edmonds and Vousden, 1989; StoreyDISCUSSION
et al., 1990a; Firzlaff et al., 1991; Phelps et al., 1992).
There may be cellular differences in the effect of phos-Previous studies have reported conflicting results on
the relative ability of HPV 6 and HPV 16 E7 to transacti- phorylation by CKII as the latter experiments were con-
ducted in either permanent rodent or simian cell lines.vate the AdE2 promoter. Because this transactivation is
mediated by E2F and E2F is central to the regulation of Recent reports indicate that the effect of phosphorylation
at the CKII site may be to enhance binding of HPV 16proto-oncogenes (e.g., c-myc), genes encoding proteins
involved in regulating cell cycle progression (e.g., cyclin E7 to the transcription basal machinery via TBP (Massimi
et al., 1996, Phillips and Vousden, 1997). It would seemE, E2F-1), and genes encoding proteins involved in DNA
synthesis (e.g., DHFR, TK, DNA polymerase a) (Adams that the role of phosphorylation at the CKII site should be
reexamined in the natural host cell, human keratinocytes.and Kaelin, 1996; Cobrinik, 1996; DeGregori et al., 1995;
Geng et al., 1996; Slansky and Farnham, 1996), we com- The data presented in Fig. 5 indicate that the E2F site
is necessary for HPV 6 E7-mediated transactivation. It ispared the transactivating ability of HPV 6 and HPV 16 E7
proteins. Our studies demonstrate that HPV 6 E7 is less possible that other elements in the AdE2 promoter also
mediate transactivation by HPV 6 E7 and might, therefore,active than HPV 16 E7 as a transactivator of the AdE2
promoter in both primary BRK cells and primary HFKs. contribute to the differential regulation of this promoter
by HPV 16 E7 and HPV 6 E7. HPV 16 E7 transactivation,In both primary cultures, HPV 6 E7 gain of transactivation
correlates with placing a higher affinity pRb binding site for example, is also mediated, although to a lesser de-
gree, through the ATF site in this promoter (Phelps et al.,of CR2, similar to that present in HPV 16 E7, into HPV 6
E7. A difference in the activity of the HPV 6 E7 mutants 1991). Mutational analysis establishes that the super-
transactivator phenotype is seen on both the AdE2 andis seen between HFKs and BRK cells: in the former, but
not the latter, introduction of the N-terminal (CR1) amino the B-myb promoter, and therefore is, at least, affecting
p107/E2F-regulated promoters. The cis element(s) medi-acids and the higher affinity pRb binding site of HPV 16
E7 into HPV 6 E7 (HPV 6 E7R1/2) results in a transactivator ating this supertransaction has yet to be determined.
Our conclusion from these studies is that the relativeeven more active than HPV 16 E7. The basis for this
difference has not been investigated. However, this re- ability of the HPV 6 E7 and HPV 16 E7 proteins to trans-
activate an E2F-mediated promoter is promoter- and cell-sult is of particular interest as HPV 6 E7R2 (6 E7G22DH24Y)
gains ability to cooperate with ras to transform BRK cells dependent. We speculate that while HPV 16 E7 is effi-
cient in transactivating both via pRb and p107 and/or[results on similar mutants of others (Heck et al., 1992)
and our unpublished data], but, is insufficient to gain the p130, HPV 6 E7 is only efficient in transactivating via
p107 and/or p130. Thus, in BRK cells the level of trans-ability to immortalize HFKs (Hu et al., 1995). Also, both
HPV 16 E7 CR1 and HPV 16 E7 CR2 are required for HPV activation mediated by HPV 16 E7 is the sum of interac-
tions with all family members while HPV 6 E7 can only16 E7 to function as a tumor promoter in transgenic mice
(Gulliver et al., 1997). affect p107/p130. This difference is obviated in C33-A
cells since they do not regulate E2F activity via pRb. InExperiments designed to begin to address the mecha-
nism of supertransactivation showed that, in the back- addition, both E7 proteins would transactivate the B-myb
promoter comparably since pRb does not play a regula-ground of HPV 6 E7R2, mutating the PKC phosphoaccep-
tor (threonine at position 7) to an alanine does not result tory role through this promoter.
Further experiments will be necessary to understandin the generation of a supertransactivator while mutating
the phosphoacceptor to aspartic acid does. Thus, an the molecular basis of the differential effect of HPV 6 E7
and HPV 16 E7 on E2F-regulated promoters. Data in theacidic amino acid, which would be most equivalent to
the charge in HPV 16 E7 and to a threonine phosphory- literature suggest that, as with pRb binding, the ability of
HPV 6 E7 to bind p107 is reduced relative to HPV 16 E7lated by PKC, in conjunction with the region 2 mutation,
induced the supertransactivation phenotype. These data (Ciccolini et al., 1994; Hu et al., 1995; Demers et al., 1996).
The data presented here would suggest that HPV 6 E7suggest that, at least in these cells and under the condi-
tions of these experiments, phosphorylation by PKC is has a functional effect on p107/E2F complexes compara-
ble to HPV 16 E7. The difference between the functionalunlikely to be occurring and/or contributing to the activity
of HPV 6 E7. studies and binding studies are not necessarily contra-
dictory. For example, if the physiological quantity of p107While HPV 6 E7R1/2 is a supertransactivator, the activity
AID VY 8885 / 6a54$$$323 11-10-97 12:17:41 vira AP: VY
245HPV E7-MEDIATED TRANSACTIVATION
domains for Rb binding and casein kinase II phosphorylation. EMBOwere small compared to pRb, HPV 6 E7, despite its low
J. 9, 153–160.binding affinity, might be sufficient to inactivate p107 but
Boyer, S. N., Wazer, D. E., and Band, V. (1996). E7 protein of human
not pRb. In contrast, HPV 16 E7, with its higher affinity papillomavirus-16 induces degradation of retinoblastoma protein
binding site, might be sufficient to inactivate both p107 through the ubiquitin-proteosome pathway. Cancer Res. 56, 4620–
4624.and pRb.
Brokaw, J. L., Yee, C. L., and Munger, K. (1994). A mutational analysisWith respect to HPV pathogenesis, an analysis of addi-
of the amino terminal domain of the human papillomavirus type 16tional E2F-dependent promoters may help explain the
E7 oncoprotein. Virology 205, 603–607.
difference in the oncogenic potential of the two viruses. Carlotti, F., and Crawford, L. (1993). Trans-activation of the adenovirus
Both HPV 6 and HPV 16 have to be in cells in S phase E2 promoter by human papillomavirus type 16 E7 is mediated by
retinoblastoma-dependent and -independent pathways. J. Gen. Virol.in order to replicate. This is particularly challenging for
74, 2479–2486.a virus which replicates in the differentiated layers of the
Chen, C., and Okayama, H. (1987). High efficiency transformations ofepithelium. Although HPV 6 is limited in its oncogenic
mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745–2752.
potential it can, at least under some conditions, induce Cheng, S., Schmidt-Grimminger, D.-C., Murant, T., Broker, T. R., and
cells to enter S (Watanabe et al., 1992; Cheng et al., Chow, L. T. (1995). Differentiation-dependent up-regulation of the hu-
man papillomavirus E7 gene reactivates cellular DNA replication in1995). A recent report by Hurford et al. (1997) using mice
suprabasal differentiated keratinocytes. Genes Dev. 9, 2335–2349.nulligenic for pRb, p107, p130, or p107 and p130 sug-
Ciccolini, F., Di Pasquale, G., Carlotti, F., Crawford, L., and Tommasino,gests that some E2F-mediated promoters are regulated
M. (1994). Functional studies of E7 proteins from different HPV types.
by pRb, others are regulated by p107 and p130, and some Oncogene 9, 2633–2638.
are unaltered in their regulation regardless of the status Cobrinik, D. (1996). Regulatory interactions among E2Fs and cell cycle
control proteins. Curr. Top. Microbiol. Immunol. 208, 31–61.of the pRb family members. Consistent with the early
DeGregori, J., Kowalik, T., and Nevins, J. R. (1995). Cellular targets forcell culture data which had indicated that B-myb was
activation by the E2F1 transcription factor include DNA synthesis-regulated by p107/p130, the same result was seen in the
and G1/S-regulatory genes. Mol. Cell. Biol. 15, 4215–4224.p107/p130 double nulligenic mice. The data of Hurford et Demers, G. W., Espling, E., Harry, J. B., Etscheid, B. G., and Galloway,
al. (1997) suggest other E2F-mediated promoters which D. A. (1996). Abrogation of growth arrest signals by human papillo-
mavirus type 16 E7 is mediated by sequences required for transfor-might be studied to test the hypothesis that HPV 6 E7
mation. J. Virol. 70, 6862–6869.can only transactivate a subset of these promoters.
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